

1. Davis JO, Carpenter CCJ, Ayers CP, and Bahn RC. Relation of anterior pituitary function to aldosterone and corticosterone secretion in conscious dogs. *Amer J Physiol* 119:212, 1960.
2. Carpenter CCJ, Davis JO, Holman JE, Ayers CR, and Bahn RC. Studies on the response of the transplanted kidney and the transplanted adrenal gland to thoracic inferior vena caval constriction. *J Clin Invest* 40:196, 1961.
3. Davis JO, Carpenter CCJ, Ayers CR, Holman JR, and Bahn RC. Evidence for secretion of an aldosterone-stimulating hormone by the kidney. *J Clin Invest* 40:684, 1961.
4. Carpenter CCJ, Davis JO, and Ayers CR. Concerning the role of arterial baroreceptors in the control of aldosterone secretion. *J Clin Invest* 40:160, 1961.
5. Davis JO, Ayers CR, Carpenter CCJ. Renal origin of an aldosterone stimulating hormone in dogs with thoracic caval constriction and in sodium-depleted dogs. *J Clin Invest* 40:1466, 1961.
6. Carpenter CCJ, Davis JO, Ayers CR. Relation of renin, angiotensin II, and experimental renal hypertension to aldosterone secretion. *J Clin Invest* 40:2026, 1961.
7. Carpenter CCJ, Davis JO, Wallace CR, Hamilton WF. Acute effects of cardiac glycosides on aldosterone secretion in dogs with hyperaldosteronism secondary to chronic right heart failure. *Circulat Res* 10:178, 1962.
8. Ayers CR, Davis JO, Lieberman F, Carpenter CCJ, Berman M. Effects of chronic hepatic venous congestion on metabolism of aldosterone. *J Clin Invest* 41:884, 1962.
9. Davis JO, Hartroft PM, Titus EO, Carpenter CCJ, Ayers CR, Spiegel HE. The role of the renin-angiotensin system in the control of aldosterone secretion. *J Clin Invest* 41:378, 1962.
10. Davis JO, Carpenter CCJ, Ayers CR. Relation of renin and angiotensin II to the control of aldosterone secretion. *Circulat Res* 11:171, 1962.
11. Davis JO, Holman JE, Carpenter CCJ, Urquhart J, Higgins JT. An extra-adrenal factor essential for chronic sodium retention in presence of increased sodium-retaining hormone. *Circulat Res* 14:17, 1964.
12. Carpenter CCJ, Mondal A, Mitra PP, Mondal H. Green coconut water: A readily available source of potassium for the cholera patient. *Bull Calcutta Sch of Trop Med* 12:20, 1964.
13. Carpenter CCJ, Solomon N, Silverberg SG, Bledsoe T, Northcutt RC, Klinenberg JR, Bennett IL, Harvey AM. Schmidt's syndrome (thyroid and adrenal insufficiency): a review of the literature and a report of 15 new cases including 10 instances of coexistent diabetes mellitus. *Medicine* 43:153, 1964.
14. Folger GM, Roberts WC, Mehrizi A, Shah DK, Glancy DL, Carpenter CCJ, Esterly JR. Cyanotic malformation of the heart with pheochromocytoma: report of 5 cases. *Circul* 29:750, 1964.

15. Carpenter CCJ, Mitra PP, Sack RB, Wells SA, Dans PE, Saxena RS, Mondal A. Metabolic and therapeutic studies on cholera. *Bull Calcutta School of Trop Med* 11:87, 1963.
16. Carpenter CCJ, Chaudhuri RN, Mondal A. A simple effective therapy of cholera. *Indian J Med Res* 52:924, 1964.
17. Carpenter CCJ. The pathophysiology of cholera. *Indian J Med Res* 52:887, 1964.
18. Carpenter CCJ, Sack RB, Mitra PP, Mondal A. Tetracycline therapy in cholera. *Bull Calcutta Sch of Trop Med* 12:30, 1964.
19. Carpenter CCJ, Mitra PP, Sack RB, Dans PE, Wells SA, Chaudhuri RN. Clinical evaluation of fluid requirements in Asiatic cholera. *The Lancet* i:726, 1965.
20. Carpenter CCJ, Barua D, Wallace CK, Sack RB, Mitra PP, Werner AS, Duffy TE, Oleinick A, Lewis GW. Clinical and physiologic observations during an epidemic outbreak of non-vibrio cholera-like disease in Calcutta. *Bull WHO* 33:665, 1965.
21. Carpenter CCJ, Wallace CK, Mitra PP, Sack RB, Mondal A, Wells SA, Dans PE, Lewis GW, Chaudhuri RN. Antibiotic therapy in cholera, p. 190, *Proc Cholera Res Symposium*, U.S. Government Printing Office, Washington, 1965.
22. Carpenter CCJ, Sack RB, Mitra PP, Dans PE, Wells SA, Chaudhuri RN. Physiologic studies during correction of base-deficit acidosis in cholera. *Proc Cholera Research Symposium*, U.S. Government Printing Office, Washington, 1965.
23. Carpenter CCJ, Mitra PS, Sack RB, et. al. Clinical studies in Asiatic cholera. I-VI. *Bull Johns Hopk Hosp* 118:165, 1966.
24. Sack RB, Carpenter CCJ, Steenburg RW, and Pierce NF. Experimental cholera: a canine model. *The Lancet* 2:206, 1966.
25. Sack RB, Barua D, Saxena R, Carpenter CCJ. Vibriocidal and agglutinating antibody patterns in cholera patients. *J Infect Dis* 116:630, 1966.
26. Carpenter CCJ, Biern RO, Mitra PP, Sack RB, Dans PE, Wells SA, Khanra SS. The electrocardiogram in Asiatic cholera: separated studies of effects of hypovolemia, acidosis and potassium loss. *Brit Heart J* 29:1, 1967.
27. Wallace CK, Carpenter CCJ, Mitra PP, Sack RB, Khanra SR, Werner AS, Duffy TE, Oleinick SS, Lewis GW. Classical and el tor cholera: a clinical comparison. *Brit Med J* 2:447, 1966.
28. Carpenter CCJ, Sack RB, Feeley JC, Steenburg, RW: Site and characteristics of electrolyte loss and effect of intraluminal glucose in experimental canine cholera. *J Clin Invest* 47:1210, 1968.
29. Carpenter CCJ, Greenough WB. Response of the canine duodenum to intraluminal challenge with cholera exotoxin. *J Clin Invest* 47:2600, 1968.

30. Curlin GT, Subong A, Craig JP, Carpenter CCJ: Antitoxin immunity in experimental canine cholera. *Trans Assoc Amer Phys* 81:314, 1968.
31. Carpenter CCJ, Greenough WB, Sack RB. Relationship of superior mesenteric artery blood flow to gut electrolyte loss in experimental cholera. *J Infect Dis* 119:182, 1969.
32. Sack RB, Carpenter CCJ. Experimental canine cholera. I. Development of the model. *J Infect Dis* 119:138, 1969.
33. Sack RB, Carpenter CCJ. Experimental canine cholera. II. Production by cell-free Vibrio cholerae culture filtrates. *J Inf Dis* 119:158, 1969.
34. Sack RB, Carpenter CCJ: Experimental canine cholera. III. Serological studies and re-challenge experiments. *J Infec Dis* 119:158, 1969.
35. Sack RB, Carpenter CCJ, Yardley JH, Subong A. Experimental canine cholera. IV. The chronic vibrio carrier state. *J Infect Dis* 119:165, 1969.
36. Chaudhuri RN, Carpenter CCJ: Treatment of cholera in 1968. *J Ind Med Assoc* 51:182, 1968.
37. Carpenter CCJ. Cholera research: United States-Japan Cooperative Medical Science Program. *Science* 159:1262, 1968.
38. Carpenter CCJ, Curlin GT, Greenough WB. Response of canine Thiry-Vella loops to cholera exotoxin and its modification by ethacrynic acid. *J Infect Dis* 120:332, 1969.
39. Greenough WB, Carpenter CCJ. Fluid loss in cholera: a current perspective. *Tex Rep Biol Med* 27:203, 1969.
40. Carpenter CCJ, Wallace CK: Bacterial endocarditis: current concepts. *Johns Hopk Med J* 124:339, 1969.
41. Curlin GT, Carpenter CCJ. Antitoxic immunity in isolated perfused canine ileal segments. *J Infect Dis* 121:S132, 1970.
42. Elliott HL, Carpenter CCJ, Sack RB, Yardley JH. Small bowel morphology in experimental canine cholera. A light and electron microscopic study. *Lab Invest* 2w:112, 1970.
43. Greenough WB, Carpenter CCJ, Bayless TM, Hendrix TR. The role of cholera exotoxin in the study of intestinal water and electrolyte transport. *Progress in Gastroenterology* 2:236, 1970.
44. Pierce NF, Carpenter CCJ, Elliott HL, Greenough WB. Effects of prostaglandins and theophylline on net transmural water and electrolyte movement in the canine jejunum. *Gastroenterology* 60:22, 1971.
45. Pierce NF, Greenough WB, Carpenter CCJ. *Vibrio cholerae* enterotoxin and its mode of action. *Bact Rev* 25:1, 1971.

46. Carpenter CCJ. Cholera enterotoxin - recent investigations yield insights into transport processes. *Amer J Med* 50:1, 1971.
47. Carpenter CCJ. Cholera: diagnosis and treatment. *Bull NY Acad Med* 47:1192, 1971.
48. Van Heyningen WE, Carpenter CCJ, Pierce NF, Greenough W.B.: Deactivation of cholera toxin by ganglioside. *J Infect Dis* 124:415, 1971.
49. Carpenter CCJ, Hirschhorn N. Pediatric cholera: current concepts. *J Pediat* 80:874, 1972.
50. Zinnaka Y, Carpenter CCJ. An enterotoxin produced by non-cholera vibrios. *Johns Hopk Med J* 131:403, 1972.
51. Pierce NF, Guerrant RL, Wallace CK, Carpenter CCJ. Recent observations on the pathophysiologic effects of E. Coli enterotoxin. Proceedings of the 8th Joint Conference U.S. Japan Cooperative Medical Science Program, Pg. 62, Fuji Printing, Co., Ltd., Tokyo, 1972.
52. Carpenter CCJ. Cholera and other enterotoxin-related diarrheal illnesses. *J Infect Dis* 126:551, 1972.
53. Guerrant RL, Ganguly V, Casper AGT, Moore EJ, Pierce NF, Carpenter CCJ. Effect of Escherichia Coli on fluid transport across canine small bowel. *J Clin Invest* 52:1707, 1973.
54. Johnson J, Casper AGT, Carpenter CCJ. Effect of desoxycorticosterone of potassium concentration in enterotoxin-stimulated small intestinal secretions. *Johns Hopk Med J* 133:201, 1973.
55. Guerrant RL, Carpenter CCJ, Pierce NF. Experimental E. coli diarrhea: Effects of viable bacteria and enterotoxin. *Trans Assoc Am Phys* 86:111, 1973.
56. Warren KS, Mahmoud AAF, Boros DL, Rall TW, Mandel MA, Carpenter CCJ: In vivo suppression by cholera toxin of cell-mediated foreign body inflammatory responses. *J Immun* 112:996, 1974.
57. Wands JR, Walker JA, Davis TT, Waterbury LA, Owens AH, Carpenter CCJ. Hepatitis B in an oncology unit. *New Engl J Med* 291:1371, 1974.
58. Carpenter CCJ. Cholera. *Preventive Medicine* 3:456, 1974.
59. Guerrant RL, Carpenter CCJ. Diarrheagenic effect of volume expansion: Intestinal fluid secretion without mucosal adenyl cyclase stimulation. *Johns Hopkins Med J* 136:209-211, 1975.
60. Stoliar OA, Pelley RP, Kaniecki-Green E, Klaus MH, Carpenter CCJ. Secretory IgA against enterotoxins in breast milk. *The Lancet* 1:1258, 1976.
61. Carpenter CCJ. Treatment of cholera - Tradition and authority versus science, reason, and humanity. *Johns Hopkins Med J* 139:153, 1976.
62. Carpenter CCJ. More pathogenic vibrios. Editorial. *New Engl J Med* 300:81, 1979.

63. Carpenter CCJ. Clinical and pathophysiological features of diarrhea caused by Vibrio cholerae and Escherichia coli. In *Secretory Diarrheas*, Field, Fortran and Schultz, eds., William and Wilkins, Baltimore, 1980.
64. Carpenter CCJ. Myths, mandarins and molecules: The cautionary tale of cholera. *Trans Am Clin Climatol Assoc* 92:167, 1981.
65. Carpenter CCJ. The pathophysiology of secretory diarrheas. *Med Clin North America* 66:597, 1982.
66. Carpenter CCJ. Oral rehydration: is it good enough for the developed world? Editorial. *New Engl J Med* 306:1103, 1982.
67. Kazura JW, Saxinger C, Forsyth K, Lederman MM, Gillespie JA, Carpenter CCJ, Alpers M. Epidemiology of human T-cell leukemia virus type-I infection in East Sepik Province, Papua, New Guinea. *J Infect Dis* 155:1100-1108, 1987.
68. Carpenter CCJ, Greenough WB III, Dale CB. Introduction and background: Symposium on oral rehydration therapies. *J Diarrhoeal Dis Res* 5(4):247-249, 1987.
69. Carpenter CCJ, Mayer K: *Advances in AIDS*. *Advances in Int Med* 33:45-80, 1988.
70. Carpenter CCJ, Greenough WB, Pierce NF. Oral-rehydration therapy - the role of polymeric substrates. *New Engl J Med* 319:1346-1348, 1988.
71. Carpenter CCJ. Today's Challenge: Rigorous Biomedical Science, Globally Applied. Presidential Address, Association of American Physicians. *Trans Assoc Am Phys* 101:cxx-cxxiii, 1988.
72. Carpenter CCJ, Mayer KH, Fisher A, Desai MB, Durand L. Natural history of AIDS in women in Rhode Island. *Am J Med* 86:771-775, 1989.
73. Carpenter CCJ. Mycobacterial tuberculosis infection with psoas abscesses. Case Records of the Massachusetts General Hospital. *NEJM* 320(12):790-9, 1989.
74. Zierler S, Laufer D, Feingold L, Kantrowitz-Gordon I, Carpenter CCJ, Mayer K. Heterosexual behavioral and HIV infection: the New England Behavioral Health Study. *RI Med* 73:285-292, 1990.
75. Imam N, Carpenter CCJ, Mayer KH, Fisher A, Stein M, Danforth SB. Hierarchical pattern of mucosal candida infections in HIV-seropositive women. *Am J Med* 89:142-146, 1990.
76. Carpenter CCJ. State-of-the-art conference on azidothymidine therapy for early HIV infection. *Am J Med* 89:335-44, 1990.
77. Carpenter CCJ. Recommendations for Zidovudine: early infection. *JAMA* 263(12):1606-9, 1990.

78. Stein MD, Piette J, Mor V, Wachtel TJ, Fleischman J, Mayer KH, Carpenter CCJ. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. *J Gen Int Med* 6:35-40, 1991.
79. Carpenter CCJ, Mayer KH, Stein MD, Leibman BD, Fisher A, Fiore TC. HIV infection in North American women: experience with 200 cases and a review of the literature. *Medicine* 70(5):307-325, 1991.
80. Stein MD, Leibman B, Wachtel TJ, Carpenter CCJ, Fisher A, Durand L, O'Sullivan PS, Mayer KH. HIV-positive women: reasons they are tested for HIV and their clinical characteristics on entry into the health care system. *J Gen Int Med* 6:286-289, 1991.
81. Mayer KH and Carpenter CCJ. Women and AIDS. *Scientific American* p.118, March, 1992.
82. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter CCJ. Quality of life in persons with human immunodeficiency virus infection: measurement by the medical outcomes study instrument. *Ann Int Med* 116:129-37, 1992.
83. Carpenter CCJ. The treatment of cholera: clinical science at the bedside. *J Inf Dis* 166:2-14, 1992.
84. Stein M, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, Fort G, Carpenter C, Skowron G, Mayer K. Causes of death in persons with human immunodeficiency virus infection. *Am J Med* 93:387-90, 1992.
85. Flanigan TP, Imam N, Lange N, Fiore T, Hoy J, Stein M, Carpenter CCJ. Decline of CD4 lymphocyte counts from the time of seroconversion in HIV-positive women. *J Wom Hlth* 1:231-4, 1992.
86. Carpenter CCJ, Flanigan TP. HIV infection in women. *AIDS/HIV Treatment Directory* 5:5-10, 1992.
87. Flanigan TP, Cu-Uvin S, Fiore T, Vigilante K, Kizirian J, Carpenter CCJ. HIV infection in Rhode Island women. *RI Med* 76:463-466, 1993.
88. Dixon PS, Flanigan TP, DeBuono BA, Laurie JJ, DeCiantis ML, Hoy J, Stein M, Scott HD, Carpenter CCJ. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. *Am J Med* 95:629-635, 1993.
89. Sande ME, Carpenter CCJ, Cobbs CG, Holmes KK, Sanford JD. Anti-retroviral therapy for adult HIV infected patients: Recommendations from a state-of-the-art conference. *JAMA* 270:2583-2589, 1993.
90. Stein MD, Flanigan TP, Carpenter CCJ, Jesdale W, Bettencourt F, Fiore T, Hutchins D, Fisher A, Mayer K. The changing presentation of HIV disease in women in Rhode Island. *J Wom Hlth* 2:367-371, 1993.
91. Cu-Uvin S, Flanigan TP, Carpenter CCJ. Routine gynecologic monitoring of HIV-seropositive women: research and recommendations. *AIDS Reader* 3:133-40, 1993.

92. Flanigan TP, Cu-Uvin S, Carpenter CCJ, Vigilante K. Spectrum of clinical illness among women infected with the human immunodeficiency virus. *Opportunistic Complications of HIV* 2:15-22, 1993.
93. Cu-Uvin S, Flanigan TP, Rich JD, Mileno MD, Mayer KH, Carpenter CCJ. Human immunodeficiency virus infection and acquired immunodeficiency syndrome in North American women. *Am J Med* 101:316-22, 1996.
94. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et. al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. *JAMA* 276:146-54, 1996.
95. Ahmed A, Watson EN, Carpenter CCJ. Does antecedent splenectomy alter the course of HIV infection? *RI Med* 79:331-2, 1996.
96. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et. al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. *JAMA* 277:1962-9, 1997.
97. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et. al. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA panel. *JAMA* 280(1):78-86, 1998.
98. Cu-Uvin S, Caliendo AM, Reinert SE, Mayer KH, Flanigan TP, Carpenter CCJ. HIV-1 in the female genital tract and the effect of antiretroviral therapy. *AIDS* 12:826-7, 1998.
99. Dickinson BP, Mitty JA, Mylonakis E, Rich JD, Meriman NA, Tashima KT, Carpenter CCJ, Flanigan TP. Predictors of undetectable HIV plasma viral load in 250 HIV-positive women receiving care. *AIDS* 12:2075-6, 1998.
100. Feinberg MB, Carpenter C, Fauci AS, Stanley SK, Cohen O, Bartlett JG, Kaplan JE, Abrutyn E. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. *Ann Int Med* 128:12(2):1057-1100, 1998.
101. Mylonakis E, Koutkia P, Rich JD, Tashima KT, Fiore TC, Flanigan T, Carpenter CCJ. Substance abuse is responsible for most pre-AIDS deaths among women with HIV infection in Providence, Rhode Island, USA. *AIDS* 12(8):958-9, 1998.
102. Santiago ML, Santiago EG, Hafalla JCR, Manalo MA, Orantia L, Cajimat MNB, Martin C, Cuaresma C, Dominguez CE, Borromeo ME, De Groot AS, Flanigan TP, Carpenter CCJ, Mayer KH, Ramirez BL. Molecular epidemiology of HIV-1 infection in the Philippines, 1985 to 1997: Transmission of subtypes B and E and potential emergence of subtypes C and F. *JAIDS* 18(3):260-9, 1998.
103. Schuman P, Sobel JD, Ohmit E, Mayer KH, Carpenter CCJ, Rompalo A, Duerr A, Smith D, Warren D, Klein RS. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. *Clin Infect Dis* 27:1161-7, 1998.

104. Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, Tashima KT, Carpenter CCJ. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). *JAIDS* 21:107-13, 1999.
105. Rompalo AM, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg SD, Warren DL, Farzadegan H, Vlahov D, Smith DK for the HER Study Group. Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. *JAIDS* 20:448-54, 1999.
106. Rich JD, Merriman NA, Mylonakis E, Greenough TC, Flanigan TP, Mady BJ, Carpenter CCJ. Misdiagnosis of HIV by HIV-1 plasma viral load testing: a case series. *Ann Int Med* 130:37-9, 1999.
107. Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CCJ. Modified directly observed therapy for treatment of human immunodeficiency virus. *JAMA* 282:1334, 1999.
108. Starr J, Powrie R, Cu-Uvin S, Carpenter CCJ. Should women with human immunodeficiency virus be delivered by cesarean? *Obstetrics & Gynecology* 94:799-801, 1999.
109. Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, et. al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel. *JAMA* 283(3):381-90, 2000.
110. Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, Mayer KH, Carpenter CCJ. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. *AIDS* 14:415-21, 2000.
111. Harrington M, Carpenter CCJ. Hit HIV-1 hard, but only when necessary. *The Lancet* 355(9221):2147-52, 2000.
112. Osowiecki DM, Cohen RA, Morrow KM, Paul RH, Carpenter CCJ, Flanigan T, Boland RJ. Neurocognitive and psychological contributions to quality of life in HIV-1 infected women. *AIDS* 14:1327-32, 2000.
113. Shacklett BL, Cu-Uvin S, Beadle TJ, Pace CA, Fast NM, Donahue SM, Caliendo AM, Flanigan TP, Carpenter CCJ, Nixon DF. Quantification of HIV-1 specific T-cell responses at the mucosal cervicovaginal surface. *AIDS* 14:1911-5, 2000.
114. Carpenter CCJ. Gender differences in HIV-associated fat redistribution—A clue to pathogenesis? (Editorial comment) *The AIDS Reader* 592, 2000.
115. Cohen RA, Boland R, Paul R, Tashima KT, Schoenbaum EE, Celentano DD, Schuman P, Smith DK, Carpenter CCJ. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. *AIDS* 15:341-5, 2001.
116. Phelps RM, Smith DK, Heilig CM, Gardner LI, Carpenter CCJ, Klein RS, Jamieson DJ, Vlahov D, Schuman P, Holmberg SD for the HER Study Group. Cancer incidence in women with or at risk for HIV. *Int J Cancer* 94:753-7, 2001.

117. Mahajan AP, Tashima KT, Bausserman LL, Flynn MM, Carpenter CCJ. Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART): a 3.5 year study. *JAIDS* 28:332-5, 2001.
118. Tashima KT, Hogan JW, Gardner LI, Korkontelou C, Schoenbaum EE, Schuman P, Rompalo A, Carpenter, CCJ. A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. *Clin Inf Dis* 33:2055-60, 2001.
119. Cu-Uvin S, Hogan JW, Caliendo AM, Harwell J, Mayer KH, Carpenter CCJ for the HIV Epidemiology Research Study. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. *Clin Inf Dis* 33:894-6, 2001.
120. Carpenter CCJ. Initial antiretroviral regimens. In general three drugs are better than two are better than one. *BMJ* 324:748-8, 2002.
121. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002. *JAMA* 288:222-35, 2002.
122. Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CCJ, Thyagarajan P, Solomon S. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. *JAIDS* 31:378-83, 2002.
123. Kumarasamy N, Flanigan T, Mahajan AP, Carpenter CCJ, Mayer KH, Solomon S. Monitoring HIV treatment in the developing world. *The Lancet* 2:656-7, 2002.
124. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CCJ, Rompalo AM, Schuman P, Klein RS, for the HIV Epidemiology Research Study Group. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. *JAIDS* 32:203-9, 2003.
125. Tashima KT, Carpenter CCJ. Fusion inhibition – A major but costly step forward in HIV-1 treatment. *N Engl J Med* 348:2249-50, 2003.
126. Jones CY, Hogan J, Snyder B, Klein RS, Rompalo A, Schuman P, Carpenter CCJ for the HIV Epidemiology Research Study Group. Overweight and human immunodeficiency virus (HIV) progression in women: Associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. *Clin Inf Dis* 37:S69-80, 2003.
125. Mayer KH, Hogan JW, Smith D, Klein RS, Schuman P, Margolick JB, Korkontzelou C, Farzedegan H, Vlahov D, Carpenter CCJ. Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy. *JAIDS* 33:614-24, 2003.

126. Harwell JI, Flanigan TP, Mitty JA, Macalino GE, Caliendo AM, Ingersoll J, Stenzel MS, Carpenter CCJ, Cu-Uvin S. Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence. *AIDS* 17(13):1990-3, 2003.
127. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CCJ, Rompalo AM, Schuman P, Klein RS. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. *JAIDS* 32:203-9, 2003.
128. Smith DK, Gardner LI, Phelps R, Hamburger ME, Carpenter CCJ, Klein RS, Rompalo A, Schuman P, Holmberg S. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. *J Urb Hlth* 80(4):676-88, 2003.
129. Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S, Carpenter CCJ, Mayer KH, Flanigan TP. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: Implications for monitoring in resource-limited settings. *JAIDS* 36:567-75, 2004.
130. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CCJ, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society-USA panel. *JAMA* 292(2):251-65, 2004.
131. Bausserman LL, Tashima KT, DiSpigno M, Maceroni D, Carpenter CCJ. Racial differences in serum lipids in HIV+ women treated with protease inhibitor regimens. *HIV Clin Trials* 5(6):399-405, 2004.
132. Beckwith CG, Flanigan TP, del Rio C, Simmons E, Wing EJ, Carpenter CCJ, Bartlett JG. It is time to implement routine, not risk-based, HIV testing. *Clin Inf Dis* 40:1037-40, 2005.
133. Kumarasamy N, Vallabhaneni S, Flanigan TP, Balakrishnan P, Cecelia A, Carpenter CCJ, Solomon S, Mayer KH. Rapid viral load suppression following generic highly active antiretroviral therapy in southern Indian HIV-infected patients. *AIDS* 19:625-7, 2005.
134. Rogers MC, Gopalakrishnan G, Kumarasamy N, Flanigan TP, Carpenter CCJ, Mayer KH, Solomon S. HIV in couples in South India; implications for prevention. *Int J STD & AIDS* 16:442-5, 2005.
135. Carpenter CCJ. Review. When germs travel: six major epidemics that have invaded America since 1900 and the fears they have unleashed. *JAMA* 293:1673-4, 2005.
136. Kumarasamy N, Ballabhaneni S, Cecelia AJ, Mayer KH, Solomon S, Carpenter CCJ, Flanigan TP. Safe discontinuation of primary pneumocystis prophylaxis in southern Indian HIV-infected patients on highly active antiretroviral therapy. *J Acquir Immune Def Syndr* 40(3):377, 2005.
137. Carpenter CCJ. Universal access to antiretroviral therapy: When, not if. Editorial *Clin Inf Dis* 42:260-1, 2006.

BOOKS, BOOK CHAPTERS OR SECTIONS:

1. Cholera, In Principles of Internal Medicine, 5th, 6th and 7th Editions TR, Harrison ed, McGraw-Hill, New York, 1966, 1970, and 1973.
2. Cholera, In a Manual of Tropical Medicine, 4th and 5th Editions, Hunter, Frye and Swartzwelder, ed, Saunders, Philadelphia, 1966 and 1974.
3. Pneumonia, Diseases of Medical Management, and Management of Medical Emergencies, in Osler's Principles and Practice of Medicine, 17th Edition, AM Harvey, ed, Appleton-Century-Crofts, New York, 1968.
4. Cholera, In Gastroenterologic Medicine, 1st Edition, M. Paulson, ed, Lea and Febiger, Philadelphia, 1969.
5. Possible role of secretory antibodies in cholera, in The Secretory Immunologic System, DH Dayton, ed, U.S. Government Printing Office, Washington, 1970.
6. Pathogenesis and pathophysiology of cholera, In Principles and Practice of Cholera Control, World Health Organization, Geneva, 1970.
7. Cholera, In Pediatrics, 15th Edition, HL Barnett, ed, Appleton-Century-Crofts, New York, 1972.
8. Cholera, In Current Therapy, 1972 edition, HF Conn, ed, W.B. Saunders, Philadelphia, 1972.
9. Cholera, In Infectious Diseases, 1st Edition. P.D. Hoeprich, ed., Harper and Row, New York, 1972.
10. Pneumonia, Bacteremia and Endocarditis, Diseases of Medical Management, and Management of Medical Emergencies, in the Principles and Practice of Medicine, 18th Edition, AM Harvey, ed, Appleton-Century-Crofts, New York, 1972.
11. Pathogenesis and Pathophysiology of cholera, and the treatment of Cholera, In Cholera, D. Barua and W. Burrows, ed, W.B. Saunders, Philadelphia, 1973.
12. Cholera and Other Enterotoxic Infections, In Principles of Internal Medicine, Thorn, Adams, Braunwald, Isselbacher and Petersdorf, ed, McGraw-Hill, New York, 1977.
13. Cholera and Diarrheal Disease caused by Escherichia coli, In Infectious Diseases, 2nd, 3rd, and 4th Editions, P.D. Hoeprich, ed, Harper and Row, New York, 1977, 1982, and 1987.
14. Diarrheas caused by bacterial pathogens, In Clinical Concepts of Infectious Diseases, L.E. Cluff and J.E. Johnson, ed., Williams and Wilkins, 2nd and 3rd Editions, 1977 and 1982.
15. Cholera, In Pediatrics, 16th and 17th edition, A.M. Rudolph, H.L. Barnett, and A.H. Einhorn, eds, Appleton-Century-Crafts, New York, 1977 and 1980.

16. Shigellosis and Cholera. In Textbook of Medicine, 15th edition, Beeson, McDermott and Wyngaarden, eds, W.B. Saunders, Philadelphia, 1979.
17. *Vibrio parahaemolyticus*. In Infectious Diseases, Mandell, Douglas and Bennett, eds, J. Wiley, New York, 1979.
18. Acute Infectious Diarrheal Disease and Bacterial Food Poisoning, and Cholera and *Vibrio Parahaemolyticus* Infections. In Principles of Internal Medicine, Isselbacher, Adams, Braunwald, Petersdorf and Wilson, ed, McGraw-Hill, New York, 9th Edition, 1980.
19. Infectious Diarrheal Syndromes. In Harrison's Updates of Internal Medicine, Isselbacher, Adams, Braunwald, Petersdorf and Wilson, ed, McGraw-Hill, New York, 1981.
20. Fluid and Electrolyte Therapy. In Infectious Diarrhea, Gorbach, S.O., Blackwell Scientific, Boston, 1986.
21. Cholera, and Acute Infectious Diarrheal Disease and Bacterial Food Poisoning. In Principles of Internal Medicine, Isselbacher, Adams, Braunwald, Petersdorf and Wilson, eds, McGraw-Hill, 10th and 11th Editions, 1983 and 1987.
22. Cholera. In Current Pediatric Therapy, Gellis and Kagan, eds, W.B. Saunders, Philadelphia, 1981.
23. Shigellosis. In Textbook of Medicine, 16th edition, Beeson, McDermott and Wyngaarden, eds, W.B. Saunders, Philadelphia, 1981.
24. Cholera. In Oxford Textbook of Medicine, Ledingham, Warrell and Weatherall, eds, Oxford University Press, Oxford, 1st and 2nd Editions, 1983 and 1987.
25. Introduction to Microbial Diseases, and Shigellosis, In Textbook of Medicine, 17th and 18th Editions, Wyngaarden and Smith, eds, W.B. Saunders, Philadelphia, 1984 and 1988.
26. Cecil Essentials of Medicine. 1st and 2nd Editions, Andreoli TE, Carpenter CCJ, Plum F, and Smith LH, eds. W.B. Saunders, Philadelphia, Pennsylvania, 1986 and 1990.
27. Malaria: Obstacles and Opportunities. Oaks SC, Mitchell VS, Pearson GW and Carpenter CCJ, eds. National Academy Press, Washington, DC, 1991.
28. Cecil Essentials of Medicine. 3rd and 4th Editions, Andreoli TE, Bennett J.C., Carpenter CCJ, Plum F, Smith LH, eds. W.B. Saunders, Philadelphia, Pennsylvania, 1993 and 1996.
29. Differential Diagnosis. 4th Edition, Barondess JA and Carpenter CCJ. Lea & Febiger, Malvern, Pennsylvania, 1994.
30. Text: Cecil Essentials of Medicine. 1st through 7th Editions. Andreoli TE, Carpenter CCJ, et al. Elsevier, Philadelphia, Pennsylvania, 1987-2007.
31. Guidelines for Antiretroviral Therapy. In Combination Therapy of AIDS, De Clercq EDA and Vandamme AMI, eds. Birkhauser Verlag/Switzerland, 2004.

